Clinical Trial Update: Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating denosumab for ER+/PR+ and/or HER2-negative metastatic breast cancer with bone metastases and detectable circulating tumor cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Northwestern University | Conditions: Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count | Phase 2 | Status: TERMINATED | Results posted: 2018-11-20